John Mantsch
Corporate Officer/Principal presso Marquette University
Posizioni attive di John Mantsch
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| Marquette University | Corporate Officer/Principal | - | - |
Storia della carriera di John Mantsch
Precedenti posizioni note di John Mantsch
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Promentis Pharmaceuticals, Inc.
 Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI. | Fondatore | 01/01/2007 | - |
Formazione di John Mantsch
| Louisiana State University Shreveport | Doctorate Degree |
| Allegheny College | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 5 |
Posizioni
| Founder | 1 |
| Corporate Officer/Principal | 1 |
| Doctorate Degree | 1 |
Settori
| Consumer Services | 4 |
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 1 |
|---|---|
Promentis Pharmaceuticals, Inc.
Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI. | Health Technology |
- Borsa valori
- Insiders
- John Mantsch
- Esperienza
